Cargando…

The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population

Detalles Bibliográficos
Autores principales:	Alkattan, Abdullah, Almutairi, Yousef, Alsalameen, Eman, Alkhalifah, Ahmed, Alghanim, Fatimah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216117/ https://www.ncbi.nlm.nih.gov/pubmed/33976007 http://dx.doi.org/10.4103/ijp.IJP_690_20

Ejemplares similares

Correlation between Micronutrient plasma concentration and disease severity in COVID-19 patients
por: Alkattan, Abdullah, et al.
Publicado: (2021)

Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity
por: Chae, Hyojin, et al.
Publicado: (2013)

Comparison of Triple Anti-Platelet Therapy (Aspirin, Clopidogrel, and Cilostazol) and Double Anti-Platelet Therapy (Aspirin and Clopidogrel) on Platelet Aggregation in Type 2 Diabetic Patients Undergoing Drug-Eluting Stent Implantation
por: Yang, Tae-Hyun, et al.
Publicado: (2009)

Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia
por: Alfaleh, Amjad, et al.
Publicado: (2022)

Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia
por: Alzahrani, Abdullah M., et al.
Publicado: (2013)

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome
por: Peng, Wenxing, et al.
Publicado: (2019)

Is it possible? Predicting complications and morbidity in surgical patients on clopidogrel therapy with Thrombelastography Platelet Mapping
por: Callender, Rashida, et al.
Publicado: (2013)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy
por: Tajima, Hayato, et al.
Publicado: (2018)

Genetic determinants of platelet response to clopidogrel
por: Kubica, Aldona, et al.
Publicado: (2011)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
por: Westergaard, Niels, et al.
Publicado: (2021)

The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers
por: Nasyuhana Sani, Yanti, et al.
Publicado: (2013)

CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel
por: Magavern, Emma F., et al.
Publicado: (2023)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI
por: Zhang, Qifeng, et al.
Publicado: (2018)

Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study
por: Liao, Yi-Ju, et al.
Publicado: (2022)

Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent it
por: Ahmed, Amr, et al.
Publicado: (2022)

Clopidogrel induced arthritis and fever
por: Cao, Cheng-Fu, et al.
Publicado: (2017)

Clopidogrel and morphine: Aggregation disturbance?
por: Joob, Beuy, et al.
Publicado: (2015)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

Inability to Reverse Aspirin and Clopidogrel-induced Platelet Dysfunction with Platelet Infusion
por: Cohn, Stephen M, et al.
Publicado: (2019)

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
por: Kuliczkowski, Wiktor, et al.
Publicado: (2021)

Impact of platelet endothelial aggregation receptor 1 genotypes and DNA methylation on platelet reactivity in patients with recurrent ischemic stroke treated with clopidogrel
por: Yang, Jiahui, et al.
Publicado: (2023)

Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease
por: Patel, Samir H., et al.
Publicado: (2012)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Effects of clopidogrel and prednisone on platelet function in healthy dogs
por: Thomason, John, et al.
Publicado: (2020)

Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity
por: Kille, Alexander, et al.
Publicado: (2021)

Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
por: Alfaleh, Amjad, et al.
Publicado: (2022)

European NSTEMI guidelines—return of clopidogrel?
por: Dannenberg, Lisa, et al.
Publicado: (2021)

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome
por: Liu, Jian, et al.
Publicado: (2015)

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
por: Joo, Hyung Joon, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention
por: Bergmeijer, Thomas O., et al.
Publicado: (2020)

Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke
por: Lee, Yi-Chung, et al.
Publicado: (2023)

Anti-Platelet Therapy with Clopidogrel Prevents Endothelial Dysfunction and Vascular Remodeling in Aortas from Hypertensive Rats
por: Giachini, Fernanda R., et al.
Publicado: (2014)

Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?
por: Abbas, Hafsa, et al.
Publicado: (2020)

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
por: Lomakin, Nikita, et al.
Publicado: (2019)

Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor
por: Yun, Kyeong Ho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_alnis91b5ctmkh5502o7m8d87j